دورية أكاديمية
أعرض في EDS

Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status.

التفاصيل البيبلوغرافية
العنوان: Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status.
المؤلفون: Rossing M; Center for Genomic Medicine 4113, Copenhagen University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark. caroline.maria.rossing@regionh.dk., Pedersen CB; Center for Genomic Medicine 4113, Copenhagen University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark.; Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark., Tvedskov T; Department of Breast Surgery, Rigshospitalet/Herlev-Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark., Vejborg I; Department of Radiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Talman ML; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Olsen LR; Center for Genomic Medicine 4113, Copenhagen University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark.; Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark., Kroman N; Department of Breast Surgery, Rigshospitalet/Herlev-Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark., Nielsen FC; Center for Genomic Medicine 4113, Copenhagen University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark., Jensen MB; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Ejlertsen B; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Clinical Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
المصدر: Scientific reports [Sci Rep] 2021 Jan 26; Vol. 11 (1), pp. 2259. Date of Electronic Publication: 2021 Jan 26.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Breast Neoplasms/*classification , Breast Neoplasms/*pathology , Sentinel Lymph Node/*pathology, BRCA1 Protein/metabolism ; BRCA2 Protein/metabolism ; Breast Neoplasms/metabolism ; Cohort Studies ; Female ; Humans ; Logistic Models ; Menopause ; Principal Component Analysis ; Receptors, Estrogen/metabolism ; Survival Analysis ; Tumor Burden
مستخلص: Axillary lymph node status is an important prognostic factor for breast cancer patients and sentinel lymph node biopsy (SLNB) is a less invasive surgical proxy. We examined if consecutively derived molecular subtypes from primary breast cancers provide additional predictive value for SLNB status. 1556 patients with a breast cancer > 10 mm underwent primary surgical procedure including SLNB and tumor specimens were assigned with a transcriptomics-based molecular subtype. 1020 patients had a negative sentinel node (SN) and 536 a positive. A significant association between tumor size and SN status (p < 0.0001) was found across all samples, but no association between size and SN status (p = 0.14) was found for BasL tumors. A BasL subtype was a predictor of an SN-negative status (p = 0.001, OR 0.58, 95% CI 0.38;0.90) and among the BasL, postmenopausal status was a predictor for SN-negative status (p = 0.01). Overall survival was significantly lower (p = 0.02) in patients with BasL tumors and a positive SN. Interestingly, we identified a significant correlation between hormone receptor activity and SN status within the BasL subtype. Taken together, molecular subtypes and hormone receptor activity of breast cancers add predictive value for SLNB status.
References: Acta Oncol. 2018 Jan;57(1):58-66. (PMID: 29164972)
BMC Cancer. 2015 Mar 19;15:151. (PMID: 25885340)
Biostatistics. 2007 Jan;8(1):118-27. (PMID: 16632515)
Nucleic Acids Res. 2005 Nov 10;33(20):e175. (PMID: 16284200)
Oncotarget. 2017 Feb 2;8(33):55534-55543. (PMID: 28903439)
NPJ Breast Cancer. 2020 Mar 6;6:8. (PMID: 32195331)
Breast Cancer Res Treat. 2009 Jan;113(1):181-7. (PMID: 18264760)
N Engl J Med. 2017 Nov 9;377(19):1836-1846. (PMID: 29117498)
Breast Cancer Res Treat. 2016 Jan;155(2):215-22. (PMID: 26740214)
Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6994-9. (PMID: 20335537)
Int J Surg. 2015 Sep;21:156-61. (PMID: 26253849)
Am J Surg. 2001 Oct;182(4):316-20. (PMID: 11720662)
Lancet Oncol. 2010 Oct;11(10):927-33. (PMID: 20863759)
Bioinformatics. 2012 Mar 15;28(6):882-3. (PMID: 22257669)
Eur J Surg Oncol. 2012 Dec;38(12):1211-7. (PMID: 22954526)
Cancer. 2005 Feb 1;103(3):492-500. (PMID: 15612028)
Ann Surg. 2007 Mar;245(3):452-61. (PMID: 17435553)
Nature. 2002 Jan 31;415(6871):530-6. (PMID: 11823860)
Oncol Lett. 2019 Feb;17(2):1986-1995. (PMID: 30675265)
Breast Cancer Res Treat. 2012 Aug;135(1):301-6. (PMID: 22752290)
Bioinformatics. 2004 Feb 12;20(3):307-15. (PMID: 14960456)
Ann Surg Oncol. 2012 Feb;19(2):567-76. (PMID: 21792511)
Oncogene. 2012 Mar 1;31(9):1196-206. (PMID: 21785460)
Nature. 2000 Aug 17;406(6797):747-52. (PMID: 10963602)
Nucleic Acids Res. 2015 Apr 20;43(7):e47. (PMID: 25605792)
J Clin Oncol. 2009 Mar 10;27(8):1160-7. (PMID: 19204204)
Breast. 2020 Jun;51:40-49. (PMID: 32200207)
Lancet Oncol. 2018 Nov;19(11):1516-1529. (PMID: 30337220)
N Engl J Med. 2003 Aug 7;349(6):546-53. (PMID: 12904519)
Breast Cancer Res Treat. 2008 Mar;108(2):191-201. (PMID: 18297396)
N Engl J Med. 2010 Nov 11;363(20):1938-48. (PMID: 21067385)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
Clin Breast Cancer. 2008 Jun;8(3):249-56. (PMID: 18650155)
Breast. 2015 Nov;24 Suppl 2:S26-35. (PMID: 26253814)
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74. (PMID: 11553815)
Breast Cancer Res. 2007;9(1):R4. (PMID: 17217540)
PLoS One. 2011;6(5):e20297. (PMID: 21655258)
BMC Cancer. 2019 Jan 10;19(1):45. (PMID: 30630443)
APMIS. 2012 Apr;120(4):341-7. (PMID: 22429216)
Oncogene. 2006 Mar 2;25(9):1413-9. (PMID: 16261164)
Breast Cancer Res Treat. 2015 Jan;149(1):229-36. (PMID: 25488719)
Ann Surg Oncol. 2014 Jul;21(7):2229-36. (PMID: 24664623)
Oncogene. 2006 Jun 29;25(28):3994-4008. (PMID: 16491124)
Nature. 2012 Apr 18;486(7403):346-52. (PMID: 22522925)
المشرفين على المادة: 0 (BRCA1 Protein)
0 (BRCA2 Protein)
0 (Receptors, Estrogen)
تواريخ الأحداث: Date Created: 20210127 Date Completed: 20210915 Latest Revision: 20210915
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC7838175
DOI: 10.1038/s41598-021-81538-4
PMID: 33500440
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-021-81538-4